Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab

BACKGROUND: We previously reported that in patients with HER2‐positive (HER2+) locally advanced breast cancer treated with neoadjuvant trastuzumab‐containing regimens, high HER2 to centromere enumerator probe 17 ratio on fluorescence in situ hybridization (HER2 FISH ratio) was an independent predict...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Kogawa, Takahiro, Fujii, Takeo, Wu, Jimin, Harano, Kenichi, Fouad, Tamer M., Liu, Diane D., Shen, Yu, Masuda, Hiroko, Krishnamurthy, Savitri, Chavez‐MacGregor, Mariana, Lim, Bora, Murthy, Rashmi K., Valero, Vicente, Tripathy, Debu, Ueno, Naoto T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2020
Gaiak:
Breast Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288623/
https://ncbi.nlm.nih.gov/pubmed/32003919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0611
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak